Nutrition, mobility predict early death in elderly cancer patients

Share this article:
Nutrition, Mobility Predict Early Death in Elderly Cancer Patients
Nutrition, Mobility Predict Early Death in Elderly Cancer Patients

(HealthDay News) -- Low nutritional assessment scores, poor mobility, and advanced disease predict early death after chemotherapy initiation among elderly patients with cancer, according to a study published online April 16 in the Journal of Clinical Oncology.

To investigate factors that predict death within six months of chemotherapy initiation, Pierre Soubeyran, M.D., Ph.D., of the Bordeaux Segalen University in France, and colleagues studied 348 elderly cancer patients (median age, 77.45 years) who had not had previous cancer treatment. Participants were evaluated at baseline using the abbreviated comprehensive geriatric assessment (aCGA), including the Mini-Mental State Exam, Timed Get Up and Go (GUG), Activities of Daily Living (ADL), Instrumental Activities in Daily Living (IADL), Mini Nutritional Assessment (MNA), Geriatric Depression Scale (GDS15), and comorbidities index (Cumulative Index Rating Scale-Geriatric).

The researchers found that 18.1 percent of participants had abnormal aCGA scores on the ADL, as did 73.0 percent on the IADL, 24.1 percent on the GUG, 19.0 percent on the MMS, 44.0 percent on the GDS15, and 64.9 percent on the MNA. Higher risk of early death was associated with advanced disease (odds ratio [OR], 3.9), a low MNA score (OR, 2.77), male gender (OR, 2.40), and long GUG (OR, 2.55).

"We recommend that the MNA and GUG, performed by a trained nurse, be maintained as part of routine pretreatment work-up in these patients to identify at-risk patients and to inform the decision-making process for chemotherapy," the authors write.

Several authors disclosed financial relationships with pharmaceutical companies, many of which funded the study.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

AACR: Dim light at night may increase breast cancer tumor resistance

AACR: Dim light at night may increase breast ...

Tumors in rodents exposed to dim light seemed to develop resistance to a common cancer drug.

ESMO: Herceptin may be best option for HER2 breast cancer treatment

ESMO: Herceptin may be best option for HER2+ ...

Drug should remain standard of care for HER2-positive tumors, according to new research.

ESMO: Combination treatments increase metastatic melanoma survival

ESMO: Combination treatments increase metastatic melanoma survival

Studies show improved progression-free melanoma survival for both cobimetinib combined with vemurafenib, and dabrafenib combined with trametinib.